Dark

Check out our API

BBI
Brickell Biotech, Inc. Common Stock
stock NASDAQ

Inactive

May 23, 2025

33.15USD+1310.638%(+30.80)218

Pre-market

0.00USD-100.000%(-2.35)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 18, 2022

06:12AM EST HC Wainwright & Co. Initiates Coverage On Brickell Biotech with Buy Rating, Announces Price Target of $2 Benzinga

Nov 9, 2021

06:14PM EST Brickell Biotech Q3 EPS $(0.16) Down From $(0.15) YoY, Sales $132.00K Miss $150.00K Estimate Benzinga

12:08PM EST Brickell Biotech's Return On Capital Employed Insights Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

Nov 1, 2021

04:05PM EDT Brickell Biotech to Report Third Quarter 2021 Financial Results GlobeNewswire Inc

Oct 28, 2021

02:45PM EDT Mid-Afternoon Market Update: Dow Surges 160 Points; Wolfspeed Shares Gain After Q1 Results Benzinga

12:16PM EDT Mid-Day Market Update: Nasdaq Rises Over 1%; Rafael Holdings Shares Slide Benzinga

08:26AM EDT The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug Benzinga

07:59AM EDT Brickell Biotech Prices Public Offering of Common Stock GlobeNewswire Inc

06:01AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 05.45 A.M. EDT). RTTNews

Oct 27, 2021

04:37PM EDT Brickell Biotech Reports Common Stock Offering, No Size Disclosed Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

06:56AM EDT Brickell Biotech Announces Positive Topline Results, Achieving Statistical Significance On All Primary And Secondary Endpoints, From Both U.S. Phase 3 Pivotal Clinical Studies Of Sofpironium Bromide Gel, 15% In Primary Axillary Hyperhidrosis Patients Benzinga

06:55AM EDT Brickell Biotech Announces Positive Topline Results, Achieving GlobeNewswire Inc

Sep 30, 2021

11:21AM EDT Looking Into Brickell Biotech's Return On Capital Employed Benzinga

Sep 17, 2021

08:00AM EDT Brickell Biotech to Host Key Opinion Leader Webinar on DYRK1A and GlobeNewswire Inc

Sep 8, 2021

08:30AM EDT Brickell Biotech to Participate at Upcoming September Conferences GlobeNewswire Inc

Sep 1, 2021

12:25PM EDT Brickell Biotech Acquires Rights To Candidate For Autoimmune Diseases Benzinga

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

07:15AM EDT Brickell Biotech Appoints Monica Luchi As Chief Medical Officer RTTNews

07:05AM EDT Brickell Biotech Expands Leadership Team, Appointing Dr. Monica GlobeNewswire Inc

07:01AM EDT Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases Benzinga

07:00AM EDT Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022 GlobeNewswire Inc

Aug 16, 2021

08:03AM EDT Brickell Biotech Announces Final Patient Completed Second US Phase 3 Pivotal Clinical Study Of Sofpironium Bromide Gel, 15% For The Treatment Of Primary Axillary Hyperhidrosis Benzinga

08:00AM EDT Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021 GlobeNewswire Inc

Aug 12, 2021

04:37PM EDT Brickell Biotech Q2 EPS $(0.16) Misses $(0.12) Estimate, Sales $151.00K Down From $607.00K YoY Benzinga

04:01PM EDT Final patient has completed the Phase 3 pivotal Cardigan I study; Enrollment completed in Phase 3 pivotal Cardigan II study- - -Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected to be reported in Q4 2021- - -Recent $8.1 million capital raise expected to fund operations beyond anticipated NDA submission in mid-2022 GlobeNewswire Inc

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

04:14AM EDT Earnings Scheduled For August 12, 2021 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Jul 29, 2021

08:00AM EDT Brickell Biotech to Report Second Quarter 2021 Financial Results GlobeNewswire Inc

Jul 28, 2021

08:50AM EDT Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Jul. 28, 2021: BA, SPRT, COOK, BTBT, BBI Benzinga

Jul 22, 2021

04:05PM EDT Brickell Biotech Announces Closing of $8.05 Million Bought Deal GlobeNewswire Inc

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 19, 2021

10:44PM EDT Brickell Biotech Increases Previously Announced Bought Deal GlobeNewswire Inc

05:26PM EDT Brickell Biotech Announces $5.0 Million Bought Deal Offering of GlobeNewswire Inc

Jul 6, 2021

08:00AM EDT Brickell Biotech to Participate at William GlobeNewswire Inc

Jun 30, 2021

10:50AM EDT Brickell Biotech Stock Moves Higher After Complete Enrollment In Phase 3 Studies Of Sofpironium Bromide Benzinga

07:29AM EDT The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs Benzinga

Jun 29, 2021

04:10PM EDT Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for Treatment of Primary Axillary Hyperhidrosis Benzinga

04:05PM EDT Brickell Biotech Announces Final Patient Completed in First U.S. GlobeNewswire Inc

Jun 24, 2021

08:20AM EDT Brickell Biotech Announces Initiation Of Phase 1 Study Of Sofpironium Bromide Gel In Primary Palmoplantar Hyperhidrosis Patients By Its Development Partner, Kaken Pharmaceutical In Japan Benzinga

08:00AM EDT Brickell Biotech Announces Initiation of a Phase 1 Study of GlobeNewswire Inc

Jun 1, 2021

08:00AM EDT Brickell Biotech Announces Publication of Japan Phase 3 Long-Term GlobeNewswire Inc

May 13, 2021

04:30PM EDT Brickell Biotech: Q1 Earnings Insights Benzinga

04:11PM EDT Brickell Biotech Q1 EPS $(0.15) Misses $(0.11) Estimate, Sales $17.00K Miss $50.00K Estimate Benzinga

04:01PM EDT Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study- - -Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected in Q4 2021- - -Presented results from Phase 3 open-label, long-term safety study of sofpironium bromide gel, 5% & 15% at AAD VMX 2021 GlobeNewswire Inc

08:10AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use Benzinga

04:15AM EDT Earnings Scheduled For May 13, 2021 Benzinga

Apr 29, 2021

08:00AM EDT Brickell Biotech to Report First Quarter 2021 Financial Results GlobeNewswire Inc

Apr 27, 2021

07:31AM EDT Brickell Biotech Completes Patient Enrollment In US Phase 3 Pivotal Cardigan I Study Of Sofpironium Bromide Gel, 15% For The Treatment Of Primary Axillary Hyperhidrosis Benzinga

07:30AM EDT Phase 3 Pivotal Cardigan II study exceeds 50% enrollment- - -Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021 GlobeNewswire Inc

Apr 23, 2021

10:04AM EDT Brickell Biotech Reports Results from U.S. Phase 3 Open-Label, Long-Term Safety Study on Chronic Use of Sofpironium Bromide Gel As Treatment For Primary Axillary Hyperhidrosis Benzinga

10:01AM EDT Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment GlobeNewswire Inc

Apr 16, 2021

10:53AM EDT Brickell Biotech Announces Presentation Of US Phase 3 Long-Term Safety Study Results For Sofpironium Bromide Gel RTTNews

10:03AM EDT Brickell Biotech Announces Presentation Of US Phase 3 Open-Label Long-Term Safety Study Results For Sofpironium Bromide Gel At Late-Breaking Research Program During American Academy Of Dermatology's 2021 VMX Benzinga

10:00AM EDT Brickell Biotech Announces Presentation of US Phase 3 Open-Label GlobeNewswire Inc

Apr 15, 2021

08:15AM EDT Brickell Biotech Highlights Publication Of Its HDSM-Ax Patient Reported Outcome Scale Validation Results In Journal Of Drugs In Dermatology Benzinga

08:12AM EDT Brickell Biotech Announces Publication of its HDSM-Ax Patient Reported Outcome Scale Validation Results in the Journal of Drugs in Dermatology Benzinga

08:00AM EDT Brickell Biotech Announces Publication of its HDSM-Ax Patient GlobeNewswire Inc

Mar 17, 2021

04:34PM EDT Brickell Biotech Filing Shows Registration For $50M Common Stock Shelf Offering Benzinga

04:24PM EDT Brickell Biotech CEO Robert Brown Reported Purchase of 100,000 Shares @ Avg Price of $1.18/Share in Form 4 Filing Benzinga

04:23PM EDT Brickell Biotech, Inc.: Brown Robert Busard (Director, Chief Executive Officer) Buys 100,000 @ Avg Price: $1.18 (Form4) Benzinga

Mar 10, 2021

07:26AM EST The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link Benzinga

Mar 9, 2021

04:02PM EST Brickell Biotech Q4 EPS $(0.15) Misses $(0.09) Estimate Benzinga

04:01PM EST Initiated U.S. pivotal Phase 3 clinical program (Cardigan I and II studies) evaluating sofpironium bromide gel, 15% for the treatment of primary axillary (underarm) hyperhidrosis GlobeNewswire Inc

09:17AM EST The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data Benzinga

04:09AM EST Earnings Scheduled For March 9, 2021 Benzinga

Mar 6, 2021

10:58AM EST The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings Benzinga

Mar 5, 2021

08:00AM EST Brickell Biotech, Inc. (Brickell) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will host a key opinion leader (KOL) webinar on the hyperhidrosis (excessive sweating) market on Friday, March 26, 2021 at 10:00 am EDT. GlobeNewswire Inc

Feb 23, 2021

04:01PM EST Brickell Biotech to Report Fourth Quarter and Full Year 2020 GlobeNewswire Inc

Jan 22, 2021

08:08AM EST Brickell Biotech Inc Says On Jan. 21, 2021, Co Received A Letter From Nasdaq Notifying Company That It Had Regained Compliance Benzinga

Jan 19, 2021

07:08AM EST Brickell Biotech Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% in the Journal of Dermatology Benzinga

07:00AM EST Brickell Biotech Announces Publication of Japan Pivotal Phase 3 GlobeNewswire Inc

Dec 7, 2020

07:32AM EST Brickell Biotech Doses First Patient In Second US Pivotal Phase 3 Clinical Study Evaluating ECCLOCK Benzinga

07:30AM EST Topline results from the U.S. pivotal Phase 3 programanticipated in the fourth quarter of 2021 GlobeNewswire Inc

Nov 18, 2020

07:09AM EST Brickell Biotech Announces Nov. 26 Launch Date For Sofpironium Bromide Gel, 5% In Japan By Its Development Partner, Kaken Pharmaceutical Benzinga

07:00AM EST Kaken plans to launch ECCLOCKfor the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020- - -ECCLOCKplaced on Japans National Health Insurance (NHI) drug reimbursement price list GlobeNewswire Inc

Nov 16, 2020

08:00AM EST Brickell Biotech, Inc. (Brickell) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that its management team will participate in the Piper Sandler 32nd Annual Healthcare Conference taking place December 1-3, 2020. GlobeNewswire Inc

Nov 12, 2020

04:03PM EST Brickell Biotech Q3 EPS $(0.15) Up From $(1.65) YoY, Sales $142.00K Down From $1.18M YoY Benzinga

04:01PM EST Brickell Biotech Reports Third Quarter 2020 Financial Results and GlobeNewswire Inc

04:18AM EST Earnings Scheduled For November 12, 2020 Benzinga

Nov 5, 2020

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

Nov 4, 2020

10:07AM EST Stocks Trading Near 52-Week Lows Just After Open On Wednesday, Nov. 4, 2020: NVCN, BBI, MFGP, TIG, DNK, GLOG, TRHC, HAPP, WG, TTNP, ATIF, CHEK, ARRY, GLSI, ETACW Benzinga

Oct 29, 2020

08:00AM EDT Brickell Biotech to Report Third Quarter 2020 Financial Results GlobeNewswire Inc

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 23, 2020

11:18AM EDT Why Brickell Biotech's Stock Is Trading Lower Today Benzinga

08:40AM EDT Stocks Trading Near 52-Week Lows Before Open On Friday, Oct. 23, 2020: CRBP, YGMZ, ITRM, BBI Benzinga

05:38AM EDT Brickell Biotech Priced 20.8M Share Public Offering , Warrants to Purchase 20.8M Shares Public Offering @$0.72/Share & Warrant Benzinga

Oct 6, 2020

07:11AM EDT Brickell Biotech Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis Benzinga

07:00AM EDT Primary axillary hyperhidrosis is estimated to affect over 10 million people in the U.S. GlobeNewswire Inc

Sep 25, 2020

07:05AM EDT Brickell Biotech Announces Approval Of Sofpironium Bromide Gel, 5% In Japan For Primary Axillary Hyperhidrosis RTTNews

07:04AM EDT Brickell Biotech Announces Approval Of Sofpironium Bromide Gel, 5% in Japan For Treatment Of Primary Axillary Hyperhidrosis Received By Its Development Partner, Kaken Pharmaceutical Benzinga

07:00AM EDT Japan is the first country to approve sofpironium bromide with commerciallaunch expected later this year GlobeNewswire Inc

Sep 10, 2020

04:05PM EDT Brickell Biotech to Participate in September Virtual Investor GlobeNewswire Inc

Sep 8, 2020

08:06AM EDT Japanese biopharmaceutical company AnGes, Inc. announced Tuesday a collaboration agreement with pharmaceutical company Brickell Biotech, Inc. (BBI), through which Brickell has the right to develop AnGes' proprietary investigational adjuvanted plasmid DNA vaccine intended to prevent SARS-CoV-2 (COVID-19) in the U.S., South America and certain emerging markets. RTTNews

07:40AM EDT AnGes, Brickell Announce Collaboration Deal For Development Of DNA Vaccine Candidate For COVID-19 RTTNews

07:31AM EDT Anges, Brickell Biotech Announce Collaboration Agreement For Develop Of Novel DNA Vaccine Candidate For COVID-19 In U.S. Benzinga

07:30AM EDT AnGes and Brickell Biotech Announce a Collaboration Agreement for GlobeNewswire Inc

Aug 31, 2020

04:14PM EDT Brickell Biotech Announces Issuance Of New Composition Of Matter Patent On Sofpironiuim Bromide By The Japanese Patent Office Benzinga

04:05PM EDT Brickell Biotech Announces Issuance of New Composition of Matter GlobeNewswire Inc

Aug 28, 2020

12:20PM EDT Lake Street Initiates Coverage On Brickell Biotech with Buy Rating, Announces Price Target of $6 Benzinga

10:40AM EDT Hearing Lake Street Initiates Coverage On Brickell Biotech With Buy Rating And $6 Price Target; Unconfirmed Benzinga

Aug 25, 2020

01:00PM EDT Oppenheimer Initiates Coverage On Brickell Biotech with Outperform Rating, Announces Price Target of $5 Benzinga

07:20AM EDT Hearing Oppenheimer Initiates Coverage On Brickell Biotech With Outperform Rating; Unconfirmed Benzinga

Aug 21, 2020

04:22PM EDT Brickell Biotech On Aug. 17 Received Notice From Nasdaq Listing Qualifications Department Benzinga

Aug 13, 2020

08:18AM EDT The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller Benzinga

Aug 12, 2020

04:03PM EDT Brickell Biotech Q2 EPS $(0.43) Up From $(6.48) YoY Benzinga

04:01PM EDT Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, Kaken GlobeNewswire Inc

04:21AM EDT Earnings Scheduled For August 12, 2020 Benzinga

Aug 3, 2020

04:05PM EDT Brickell Biotech to Report Second Quarter 2020 Financial Results GlobeNewswire Inc

Share